Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Partners With Protalix On Gaucher Drug Eyeing Lower Cost Plant-Based Production

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer agrees to pay $60 million upfront for rights to taliglucerase, an investigational competitor to Genzyme's Cerezyme.

You may also be interested in...



Pfizer/Protalix’s Elelyso Offers Gaucher Patients A Vegetarian Option

Gaucher disease enzyme-replacement therapy Elelyso is the first FDA-approved plant-cell based recombinant therapeutic protein, a biosimilar option that may eliminate the production-related problems Genzyme’s Cerezyme and Shire’s Vpriv face with animal cell-based processes. Pfizer is launching Elelyso at a 25% discount to Cerezyme and promising to maintain a two-year supply.

FDA Delays Approval Of Protalix/Pfizer Gaucher Drug; Seeks More Data From Late-Stage Trials

FDA may be seeking more safety data before approving of Uplyso, a plant cell-derived enzyme replacement therapy.

FDA Delays Approval Of Protalix/Pfizer Gaucher Drug; Seeks More Data From Late-Stage Trials

FDA may be seeking more safety data before approving of Uplyso, a plant cell-derived enzyme replacement therapy.

Related Content

Topics

UsernamePublicRestriction

Register

PS068852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel